Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Business Wire•05/11/2026•16:10 ET
0
Key Highlights
- ➤Prula-cel Phase 1: 50% of evaluable LN patients achieved complete renal response at 12 months
- ➤Prula-cel Phase 1: 54% of evaluable patients achieved DORIS remission at 12 months
- ➤Adicet initiated pivotal lupus nephritis study startup activities; FDA expansion discussions planned in 4Q/2026
- ➤FDA cleared ADI-212 IND and granted Fast Track Designation for metastatic castration-resistant prostate cancer
- ➤$100.9 million cash, equivalents and short-term investments expected to fund operations into second half of 2027
Expert Statements
Chen Schor, President and Chief Executive Officer of Adicet Bio
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”
Chen Schor, President and Chief Executive Officer of Adicet Bio
“With pivotal study startup activities underway in LN and planned FDA discussions regarding potential pivotal expansion to include lupus patients without nephritis, we look forward to providing a regulatory update and additional 12-month follow-up data from approximately 22 patients in the first quarter of 2027 followed by clinical data from our systemic sclerosis cohort in the second quarter. Together with continued progress on ADI-212 and our in vivo CAR-T pipeline, we believe 2027 will be a catalyst-rich year for Adicet.”
Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN)
Get started
Create a free account to read the full story.